Oxbryta Increased Hemoglobin, Reduced Hemolysis in Adults and Adolescents

Oxbryta Increased Hemoglobin, Reduced Hemolysis in Adults and Adolescents

291719

Oxbryta Increased Hemoglobin, Reduced Hemolysis in Adults and Adolescents

Treatment with oral Oxbryta (voxelotor) leads to rapid and sustained rises in hemoglobin levels, reduces red blood cell destruction (hemolysis), and improves overall health in adolescents and adults with sickle cell disease (SCD), according to full, nearly 1.5-year data from the Phase 3 HOPE clinical trial. The findings support the long-term benefits of Oxbryta, which was approved conditionally in the U.S. as the first treatment to tackle the underlying cause of SCD — the clumping and sticking of…

You must be logged in to read/download the full post.